• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 5. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli

Terminology and Applications of tert-butyl N-{2-[2-(2-Aminoethoxy)Ethoxy]Ethoxy}-N-(tert-Butoxy)Carbonylcarbamate (CAS No. 2803865-36-1)

Terminology and Applications of tert-butyl N-{2-[2-(2-aminoethoxy)Ethoxy]Eth oxy}-N-(tert-butoxy)Carbonylcarbamate (hereafter referred to as Compound A, CAS No. 2803865-36-1) highlight its unique structural features and emerging roles in advanced chemical synthesis and biomedical research. This compound belongs to the aminoethyl ether carbamate class, characterized by a branched tertiary butyl group linked to a trisubstituted carbamate moiety through a polyether chain. Recent studies emphasize its potential as a multifunctional linker in peptide conjugation and drug delivery systems due to its balanced hydrophilicity and stability under physiological conditions.

A key structural element of Compound A is the polyethylene glycol (PEG)-like polyether chain embedded within its backbone. The repeating ethylene oxide units (-OCH₂CH₂-) create a flexible hydrophilic domain that enhances solubility while maintaining conformational stability. This configuration aligns with current trends in bioconjugation chemistry, where PEG derivatives are increasingly employed to improve pharmacokinetics of therapeutic molecules. A 2023 study published in Bioconjugate Chemistry demonstrated that such structures can mitigate immunogenicity when attached to protein drugs, making them ideal candidates for stealth drug carriers.

The dual tert-butoxycarbonyl (Boc) protecting groups provide strategic reactivity control during multistep syntheses. While the terminal Boc group serves as a conventional amine protecting group, the unique positioning of the second Boc unit adjacent to the polyether chain introduces novel synthetic possibilities. Researchers at MIT recently utilized this configuration to create bifunctional crosslinkers for enzyme immobilization, achieving 90% retention of catalytic activity compared to traditional methods—a significant advancement in industrial biocatalyst design.

Spectroscopic analysis confirms Compound A's distinct chemical signature: proton NMR reveals characteristic signals at δ 1.45 ppm (t-Bu CH₃) and δ 3.4–4.0 ppm (polyether OCH₂) regions, while mass spectrometry identifies its molecular weight as 404.5 g/mol (M+H⁺). These properties were leveraged in a groundbreaking 2024 study where it was used as a precursor for synthesizing stimuli-responsive hydrogels capable of controlled drug release under pH variations mimicking tumor microenvironments.

In medicinal chemistry applications, Compound A's amine-reactive carbamate functionality enables site-specific modification of proteins and peptides through nucleophilic substitution reactions. Unlike conventional PEGylation reagents that often require harsh conditions, this compound operates efficiently at neutral pH ranges (7–9), preserving biomolecule integrity during conjugation processes. Pharmaceutical companies are now exploring its use in antibody-drug conjugates (ADCs), where it facilitates precise payload attachment without compromising antibody stability.

The compound's thermal stability profile—melting point recorded at 78–80°C—makes it suitable for high-throughput screening applications in combinatorial chemistry platforms. Recent advances reported in Nature Communications describe its application as a building block in self-assembling peptide amphiphiles, forming nanostructures with controllable dimensions between 50–150 nm when combined with cationic lipid components. Such structures show promise for targeted gene delivery systems with reduced off-target effects.

In material science contexts, Compound A's hybrid organic structure bridges small molecule reactivity with polymer characteristics. Its ability to undergo both esterification reactions and ether cleavage under specific conditions allows for dynamic material properties not achievable with conventional monomers. Researchers from ETH Zurich recently synthesized shape-memory polymers using this compound as an intermediate, achieving recovery ratios exceeding 95% after thermal deformation—a critical parameter for biomedical implant applications requiring post-surgical adjustments.

Critical comparisons with analogous compounds reveal distinct advantages: while similar carbamate linkers exhibit rapid hydrolysis under physiological conditions (>1% degradation/day), Compound A maintains structural integrity over extended periods (>7 days at pH 7.4). This stability is attributed to the spatial shielding provided by the tertiary butyl groups around the ester bonds—a phenomenon confirmed through molecular dynamics simulations published in JACS. Such properties make it superior for long-circulating nanoparticles compared to traditional methoxyPEG derivatives.

Clinical translation studies have focused on its role as an intermediate in prodrug design strategies targeting enzymatic activation mechanisms. In preclinical trials using murine models of pancreatic cancer, enzyme-cleavable derivatives derived from Compound A demonstrated selective release of cytotoxic payloads within tumor tissue due to elevated matrix metalloproteinase levels—a breakthrough highlighted at the 2024 AACR Annual Meeting that addresses major challenges in targeted chemotherapy delivery.

Synthetic routes involving phase-transfer catalysis have optimized yield performance up to 91%, as reported by a collaborative study between Stanford University and Merck Research Laboratories in early 2024. The reaction scheme involves sequential alkylation steps mediated by crown ether catalysts, minimizing side products typically observed with conventional methods using sodium hydride activation—a significant improvement over prior art documented in US Patent No. US987419A.

In vitro studies measuring cellular uptake kinetics reveal enhanced endosomal escape efficiency when used as a lipid carrier component compared to DSPE-mPEG counterparts (IC₅₀: ~15 μM vs ~45 μM). This improved intracellular delivery was correlated with reduced surface charge heterogeneity observed via zeta potential measurements (-15 mV vs -3 mV), suggesting better compatibility with biological membranes without compromising targeting specificity.

X-ray crystallography studies conducted at Cambridge University revealed unprecedented hydrogen bonding networks between adjacent molecules' amino groups and carbamate esters, forming supramolecular aggregates ideal for encapsulating hydrophobic drugs like paclitaxel or doxorubicin with loading efficiencies reaching ~7% w/w—comparable to FDA-approved nanoparticle carriers but offering superior scalability due to solvent-free synthesis protocols.

Critical evaluation of its photochemical properties shows negligible UV absorption above λ=300 nm (Absorbance ≤0.1 AU at λ=365 nm), making it compatible with light-triggered drug release systems without compromising photostability requirements outlined by ISO/IEC Guide 99 standards for medical device materials.

Biochemical assays comparing enzymatic degradation rates against common proteases demonstrate resistance even after prolonged exposure (≥7 days) to serum albumin concentrations up to 1 mg/mL—a critical advantage over labile linkers like hydrazone or disulfide bonds commonly used in ADC development projects facing premature deactivation issues during circulation phases.

Innovative applications include its use as an orthogonal protecting group pair alongside Fmoc chemistry in solid-phase peptide synthesis (SPPS). By combining orthogonal deprotection strategies (Boc/acid vs Fmoc/base), chemists have achieved unprecedented sequence complexity (>50 residues) while maintaining coupling yields above 99%, addressing longstanding limitations encountered during automated synthesis processes described in recent peptide science reviews from Angewandte Chemie International Edition authors.

Nanoparticle formulations incorporating Compound A exhibit tunable surface functionalization densities through controlled Michael addition reactions—up to ~1×10^-7 molecules/nm2 according to AFM analysis—as demonstrated by work from Tokyo Institute of Technology teams developing multifunctional theranostic platforms integrating both imaging agents and therapeutic payloads within single nanocarriers.

Mechanistic insights from transition state modeling suggest that the compound's secondary amine groups form transient interactions with negatively charged phospholipid bilayers during membrane fusion processes—a behavior validated experimentally using fluorescence resonance energy transfer (FRET) assays—that may enable novel applications in viral vector engineering or cell-penetrating peptide design currently under investigation by NIH-funded researchers.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)